Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fuchs' Endothelial Dystrophy Clear all
Terminated No phase listed Observational

Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only

NCT04527523
View directory record Official record
Conditions
Cystoid Macular Edema, Fuchs Dystrophy
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

NCT03248037
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Interventions
Netarsudil, Placebo
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

NCT02653391
View directory record Official record
Conditions
Fuchs' Corneal Endothelial Dystrophy (FCED)
Interventions
Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Edgewood, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321
View directory record Official record
Conditions
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions
TTHX1114(NM141), Vehicle (placebo)
Drug · Other
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 2 Interventional

TTHX1114(NM141) in Combination With DWEK/DSO

NCT04676737
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs
Interventions
TTHX1114(NM141)
Drug
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Long Beach, California • Petaluma, California • Deerfield Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 23, 2026, 2:58 PM EDT
Recruiting Phase 4 Interventional

Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy

NCT03249337
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Ripasudil hydrochloride hydrate 0.4% ophthalmic solution
Drug
Lead sponsor
Marian Macsai, MD
Other
Eligibility
18 Years to 91 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Combined Cataract Surgery and Planned Descemetorhexis

NCT02206594
View directory record Official record
Conditions
Fuchs' Corneal Dystrophy, Cataract
Interventions
Descemetorhexis
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Jul 23, 2026, 2:58 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

NCT03971357
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Netarsudil, Placebo
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

NCT04250207
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
K-321 Solution, Placebo Solution
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Jul 23, 2026, 2:58 PM EDT
Not listed Phase 4 Interventional

Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)

NCT01357122
View directory record Official record
Conditions
Fuchs' Corneal Endothelial Dystrophy
Interventions
NCI Insertion, Standard Forceps Insertion
Device · Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05795699
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

NCT04498169
View directory record Official record
Conditions
Corneal Edema
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Garden Grove, California • Laguna Hills, California • Edgewood, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jul 23, 2026, 2:58 PM EDT
Terminated Not applicable Interventional

OCT-guided DSAEK Graft Shaping and Smoothing

NCT01586234
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
DSAEK with graft shaping and smoothing, Standard DSAEK
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

NCT04051463
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Netarsudil Ophthalmic Solution, Placebo
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 23, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty

NCT00624221
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy, Corneal Edema
Interventions
Descemet's stripping endothelial keratoplasty
Procedure
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Jul 23, 2026, 2:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

NCT02118922
View directory record Official record
Conditions
Keratoconus, Ectasia, Crosslinking, Fuchs' Endothelial Dystrophy
Interventions
Brillouin imaging
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 23, 2026, 2:58 PM EDT
Terminated No phase listed Observational

Using the Optovue OCT to Select IOL Power

NCT01361282
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Cataract
Interventions
Not listed
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 23, 2026, 2:58 PM EDT